of diseases of the myocardium associated with mechanical and/or electrical dysfunction that usually but not invariably exhibit inappropriate ventricular hypertrophy or dilatation and are due to a variety of causes that frequently genetic 8 . Cardiomyopathies thus are confined to the heart or are part of a generalized systemic disorder, often leading to cardiovascular death or progressive heart failure with related disability. Cardiomyopathies were divided into two major groups based on predominant organ involvement. Primary cardiomyopathies are genetic, nongenetic, acquired and those solely or predominantly confined to heart muscle and are relatively few in number. Secondary cardiomyopathies show pathological myocardial involvement as part of a large number of generalized systemic (multi-organ) disorders. The panel recommended that cardiomyopathies can be most effectively classified as primary : genetic; mixed (genetic and nongenetic), acquired; and secondary 8 [ Table-1] . Recently, the European Society of Cardiology working group on myocardial and pericardial diseases defined, "Cardiomyopathy as a myocardial disorder in which the heart muscle is structurally and functionally abnormal, in the absence of coronary artery disease, hypertension, valvular diseases, and congenital heart disease." Cardiomyopathies were grouped into specific morphological and functional phenotypes; each phenotype was then sub-classified into familial and non-familial forms 9 [ Table-1] . About one-half of hypertrophic Cardiomyopathy occurs familially, and one-half of those patients are associated with gene mutations. Confusion arises when in some cases of nonfamilial hypertrophic Cardiomyopathy, gene mutation are not seen, on the other hand some of the dilated Cardiomyopathy showed gene mutation of hypertrophic Cardiomyopathy. Although myocarditis is believed to be the major cause of dilated cardiomyopathy, myocarditis is often associated with hypertrophic cardiomyopathy which is caused by a viral infection such as hepatitis C virus [10] [11] [12] [13] [10] [11] [12] [13] [14] . 
Comparison of classifications of cardiomyopathies

Role of viruses in the pathogenesis of cardiomyopathies
Myocarditis is one of the cardiological problem encounter in clinical practice, it is caused by many viruses and also it may represent as a part of many systemic diseases. Myocarditis is thought to be most commonly caused by enteroviruses, particularly coxsackievirus B. However, in many cases, when myocarditis has been diagnosed on the basis of clinical characteristics, no definite confirmation of viral origin is obtained, despite extensive laboratory investigations. The evidence is often only circumstantial, and a direct, conclusive proof of cardiac involvement is not available. However, accumulating evidence links viral myocarditis with the eventual development of dilated cardiomyopathy [18] [19] [20] . Affection of the heart is manifested on the variety of pathological lesions e.g. when myocardial necrosis occurs diffusely, congestive heart failure develops and later dilated cardiomyopathy. If myocardial lesions are localized, a ventricular aneurysm may form. When complicated with arrhythmias, myocarditis presents as arrhythmogenic right ventricular Cardiomyopathy 21 . When myocardial necrosis is localized to the subendocardium, restrictive Cardiomyopathy may develop 21 . While it has not been established that hypertrophic cardiomyopathy may be a complication of viral myocarditis, asymmetrical septal hypertrophy has in fact, sometimes been observed in patients with myocarditis 22 . Hepatitis B antibody was detected in 8.6% of dilated cardiomyopathy and 14.6% of hypertrophic cardiomyopathy patients. Hepatitis C antibody was present in 6.7% of dilated cardiomyopathy and 9.5% of hypertrophic cardiomyopathy patients 17 .
Recently the importance of hepatitis C virus (HCV) has been noted in patients with hypertrophic cardiomyopathy, dilated cardiomyopathy, and myocarditis 10-13, 23, 24 .
Burden of cardiomyopathies: incidence and prevalence
There are few epidemiologic data of myocarditis. The Japanese Scientists conducted nationwide epidemiological surveys of cardiomyopathies in Japan [14] [15] [16] .
Disorders surveyed included idiopathic dilated Cardiomyopathy (DCM), hypertrophic cardiomyopathy (HCM), restrictive cardiomyopathy (RCM), ARVC/D, mitochondrial disease, Fabry's disease of the heart, and prolonged Q-T interval syndrome. The Scientist estimated that 17,700 persons had dilated Cardiomyopathy (14 per 100,000), 21,900 had hypertrophic cardiomyopathy, 300 had restrictive cardiomyopathy, 520 had ARVD, 640 had mitochondrial disease, 150 had Fabry's disease of the heart, and 1000 had prolonged Q-T interval syndrome. The prevalence of both dilated cardiomyopathy and hypertrophic cardiomyopathy was higher in men than women, the men to women ratios were 2.6 and 2.3; for dilated cardiomyopathy and hypertrophic cardiomyopathy respectively. Detailed data on patients with dilated cardiomyopathy or hypertrophic Cardiomyopathy were collected by a follow-up survey. In one year, more patients with dilated Cardiomyopathy (5.6%) died than with hypertrophic Cardiomyopathy (2.8%). Congestive heart failure and arrhythmias were the leading causes of death for dilated cardiomyopathy and hypertrophic cardiomyopathy respectively. Among patients with dilated Cardiomyopathy (n = 506) and hypertrophic Cardiomyopathy (n = 330) who had myocardial biopsies, significant mononuclear cell infiltrations were seen in 24% with dilated cardiomyopathy and 15% with hypertrophic cardiomyopathy suggesting the presence of inflammation in these patients. Cardiac troponin T was increased in 3% of dilated Cardiomyopathy and 9% of hypertrophic cardiomyopathy patients. Hepatitis B antibody was detected in 8.6% of dilated cardiomyopathy and 14.6% of hypertrophic cardiomyopathy patients. Hepatitis C antibody was present in 6.7% of dilated cardiomyopathy and 9.5% of hypertrophic cardiomyopathy patients. These data suggested that hepatitis B and C virus may cause myocarditis and cardiomyopathies. Five variables, left ventricular dilatation, lower left ventricular ejection fraction, higher NYHA functional class, older age, and male sex were independently related to poor prognosis 17 .
Phenotypes of HCV cardiomyopathies
In an initial study, Japanese Scientist found HCV RNA by polymerase chain reaction in the hearts of 19% of patients with dilated cardiomyopathy 24 . Over a 10-year period, they identified 9.9% of patients with dilated cardiomyopathy had evidence of HCV infection, in contrast to only 2.5% of patients with ischemic heart disease. The main clinical manifestations at initial 
Prolonged persistence of hepatitis C virus genomes in paraffin-embedded hearts
A multicenter study by the Scientific Council on Cardiomyopathies of the World Heart Federation (Bernhard Maisch, MD, Chairman) showed HCV genomes in 18% of patients with dilated Cardiomyopathy and myocarditis from Italy, and in 36% from the United States, two from patients with myocarditis and two with ARVC 25 , which suggests that HCV may cause ARVC. In collaboration with the National Cardiovascular Center and Juntendo University, they have detected HCV RNA in paraffin sections of autopsied hearts from 26% of patients with hypertrophic cardiomyopathy, 12% of patients with dilated cardiomyopathy, and 33% of patients with myocarditis 13 . They also examined autopsied hearts from patients with dilated cardiomyopathy in a collaborative study with the University of Utah and found HCV RNA in 35% of hearts. The sequences of HCV genomes recovered from these hearts were highly homologous to the standard strain of HCV 25 . However, the rates of HCV genomes detection in the hearts of patients with cardiomyopathies varied widely among different regions of the world. For example, no HCV genome was detected in hearts obtained from St. Paul's Hospital, in Vancouver, Canada. These observations suggest that the frequency of cardiomyopathy caused by HCV infection may be different in different regions or different populations. They analyzed sera stored during the US Myocarditis Treatment Trial 27 of immunosuppression in patients with heart failure and myocarditis. Anti-HCV antibodies were identified in 4.4% of patients, including 5.9% of patients with biopsyproven myocarditis. According to the US Centers for Disease Control, the prevalence of HCV infection in the general US population is 1.8% 28 , thus HCV infection is more prevalent in patients with heart failure because of myocarditis. Furthermore, variations between 0% and 15% were found in the prevalence of HCV infection among the different medical centers and regions 29 .
Genes responsible for development of different phenotypes of HCV cardiomyopathies
The major human histocompatibility complex (MHC) is located on the short arm of chromosome 6 and encodes for several protein products involved in immune function, including complement, TNF-a, and the human leukocyte antigen (HLA) complex, the polymorphisms of which are often proposed as determinants for the susceptibility to various diseases. Recent studies of HCV hepatitis showed that DQB1*0301 was associated with clearance of the virus. DRB1*1101, which is also in linkage disequilibrium with DQB1*0301, was associated with clearance. Several other studies have examined the association of MHC alleles with the progression of liver disease, and DQB1*0401 and DRB1*0405 were more prevalent among patients who developed chronic liver disease. The Scientist found that DPB1*0401 and DPB1*0901 were significantly associated with an increased risk of HCV-hypertrophic cardiomyopathy in the dominant model. The disparity in the gene-dose effect of two susceptible DPB1 alleles may be attributable to the difference between the susceptible and resistant residue-combination consisting of the DPb anchor pocket for antigenic peptide-binding. These results implied that the HLA-DP molecules with a specificity pocket appropriate for an HCV antigen(s) might confer the progressive process of hypertrophic Cardiomyopathy in HCV-infected individuals 30 . In addition, no significant association was found between the MHC markers and HCV-hypertrophic cardiomyopathy. This marked difference in the MHC-related disease susceptibility for HCV-associated cardiomyopathy strongly suggests that the development of HCV-dilated cardiomyopathy and HCV-hypertrophic cardiomyopathy is under the control of different pathogenic mechanisms 31 .
Treatment of HCV cardiomyopathies
In patients with HCV hepatitis, the success of treatment can be measured by the biochemical and virologic 32 . This preliminary study suggests that interferon is a promising treatment for myocardial disease caused by HCV. They have also reported beneficial treatment with interferon guided by serial measurement of serum HCV RNA and cardiac troponin T in a patient presenting with dilated cardiomyopathy and striated myopathy attributable to HCV infection 33 .
Impact of HCV on vascular disease
There are several reports on the association of diabetes mellitus and HCV infection. Also, HCV infection has been reported as a risk factor of atherosclerosis 39, 40 . Therefore, it is important to clarify the role of HCV infection as a risk factor of atherosclerosis and vascular diseases, especially in the geographic areas with a high prevalence of HCV infection. The anti-viral treatment may cure the diseases, and decrease the number of patients. Thus, the cost to treat these patients and importantly, the burden of disease to the patients can be decreased [39] [40] [41] [42] .
Conclusion:
In Bangladesh, we are not very aware of Hepatitis virus induced heart disease. Some personal communication reveal that Hepatitis positive case are reported with heart failure. No proven strategy has been identified to reduce the numbers of patients living with, and dying from, cardiomyopathies and myocarditis due to infectious agents. Yet, the morbidity and mortality are high. We can treat these diseases by anti-viral agents, and some patients with cardiomyopathies and heart failure may be cured. Thus, treating these persons much earlier in the disease process-because of the ability to identify and treat HCV infection-will reduce the burden of cardiomyopathies and heart failure in patients and reduce the costs of treatment of these complex and long-term diseases.
